Method of assaying kallikrein formation substances
AssigneeNippon Zoki Pharmaceutical Co., Ltd.
InventorsYoshio Toyomaki, Katsumi Nishikawa, Hitoshi Kawakubo
Life of this patent
Estimating the term…
Abstract
A method of assaying a physiologically active substance, which comprises activating blood coagulation factor XII in plasma in the presence of said physiologically active substance being tested to convert prekallikrein in the plasma into kallikrein, and measuring the activity of kallikrein thus formed.
Claims13
A method of assaying inhibitory action of a kallikrein formation inhibitor, the method comprising forming a reaction mixture consisting essentially of (1) animal plasma, (2) an activator for blood coagulation factor XII, (3) an electrolyte and (4) a kallikrein formation inhibitor to be assayed;
- incubating said reaction mixture;
- adding an inhibitor having substantially no effect upon the kallikrein activity and being capable of specifically inhibiting activity of activated blood coagulation factor XII to substantially stop production of kallikrein in said reaction mixture, said adding occurring while a substantially linear relationship exists between reaction time and kallikrein formation;
- and measuring an amount of kallikrein thus formed.
A method of assaying inhibitory action of a kallikrein formation inhibitor, the method comprising forming a reaction mixture in which pre-kallikrein is converted to kallikrein;
- incubating said reaction mixture;
- stopping production of kallikrein in the reaction mixture by adding an inhibitor having substantially no effect upon the kallikrein activity and being capable of specifically inhibiting activity of activated blood coagulation factor XII, said adding occurring while a substantially linear relationship exists between reaction time and kallikrein formation;
- and measuring an amount of kallikrein thus formed.
Dependencies are inferred from the claim text.